. Author manuscript; available in PMC: 2021 Jan 1.

Published in final edited form as: Respir Med. 2019 Nov 20;161:105822. doi: 10.1016/j.rmed.2019.105822

Table 5.

Results from mixed effects regression analysis of CXCL9 or CXCL10 obtained over two years and immunosuppression use at time of measurement modeled in two different ways

Outcome	Main Predictor(s)^†
	Model 1: Binary Immunosuppression Use (Yes/No)

	β-coefficient^‡	(95% CI)	p-value

CXCL9	−29%	(−42, −14)	4.9x10⁻⁴

CXCL10	−28%	(−37, −17)	6.4x10⁻⁶

	Model 2: Prednisone Dose (mg/day)^§			DMARD Use (Yes/No)

	β-coefficient	(95% CI)	p-value	β-coefficient	(95% CI)	p-value

CXCL9	−0.70%	(−1.6, 0.17)	0.12	−35%	(−47, −20)	5.0x10⁻⁵

CXCL10	−9.6%	(−1.7, −0.33)	0.0034	−22%	(−34, −11)	5.1x10⁻⁴

^†

Models adjusted for age, race, and sex

^‡

Non-linear combinations of β-coefficients performed to show the %change in chemokine level for every unit increase in continuous predictor or if binary variable = Yes

^§

Prednisone dose in units of 1 mg/day

Abbreviations: CI = Confidence Interval, DMARD = disease-modifying antirheumatic drug